Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.70 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.70 |
| ▸ | MAOB | P27338 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.57 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9453126 | 0.88 | CYP4F2 (0.64) | CYP4F2CYP4A11MAOBNR4A2SPHK2 | |
| SCHEMBL7817624 | 0.88 | GSTP1 (0.60) | CYP4F2CYP4A11MAOBALDH1A1RECQL | |
| SCHEMBL9451327 | 0.87 | ALDH1A1 (0.69) | CYP4F2CYP4A11MAOBALDH1A1RECQL | |
| SCHEMBL1268719 | 0.87 | MAOB (0.81) | CYP4F2CYP4A11MAOBNR4A2BCHE | |
| Ethylene Glycol SCHEMBL28255824 | 0.86 | CYP4F2 (0.70) | CYP4F2CYP4A11MAOBALDH1A1NR4A2 | |
| SCHEMBL48418 | 0.84 | ALDH1A1 (0.70) | CYP4F2CYP4A11ALDH1A1RECQLKMT2A | |
| SCHEMBL4819108 | 0.84 | ALDH1A1 (0.64) | MAOBALDH1A1RECQLNR4A2BCHE | |
| Ethylene Glycol SCHEMBL29003668 | 0.83 | MAOB (0.87) | CYP4F2CYP4A11MAOBNR4A2SPHK2 | |
| Ethylene Glycol SCHEMBL7206927 | 0.82 | ALDH1A1 (0.67) | CYP4F2CYP4A11ALDH1A1RECQLKMT2A | |
| SCHEMBL28545402 | 0.82 | ALDH1A1 (0.62) | CYP4F2CYP4A11ALDH1A1RECQLBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108949902-A | A kind of serum small and dense low-density lipoprotein cholesterin detection reagent box | 山东博科生物产业有限公司 | 2018-12-07 | — | — | CN | claimed |
| CN-108949902-A | A kind of serum small and dense low-density lipoprotein cholesterin detection reagent box | 山东博科生物产业有限公司 | 2018-12-07 | — | — | CN | disclosed |
| CN-108949902-A | A kind of serum small and dense low-density lipoprotein cholesterin detection reagent box | 山东博科生物产业有限公司 | 2018-12-07 | — | — | CN | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1218361-B1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1939188-A1 | Oxa-and thiazole derivatives useful as antidiabetic and antiobesity agents | Bristol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1283711-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2001085170-A9 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-01-26 | — | — | WO | disclosed |
| US-6806369-B2 | N-FORMYL-N-HYDROXY-2-(5-ISOQUINOLINOXY)ETHYLAMINE ANTI-BACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2004-10-19 | — | — | US | disclosed |
| US-20040192719-A1 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | disclosed |
| US-20040053932-A1 | Peptide deformylase inhibtors | GLAXOSMITHKLINE LLC | 2004-03-18 | — | — | US | disclosed |
| EP-1283711-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1283711-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001085170-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-15 | — | — | WO | disclosed |
| US-5273993-A | Antiarthritic agents; osteoporosis | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-12-28 | — | — | US | disclosed |
| US-5194446-A | Antiarthritic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-03-16 | — | — | US | disclosed |
| US-5025031-A | Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants | A. H. ROBINS CO., INC. (US) | 1991-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053932-A1 | Peptide deformylase inhibtors | PDF, VIP, SPPL2B | CYP4F2 3285/4885CYP4A11 4236/4885MAOB 1998/4885 |
| US-20040192719-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | CYP4F2 3877/4885CYP4A11 4642/4885MAOB 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.